KEI asks NIST to extend comment period on their Special Publication 1234 Draft Green Paper on Return on Public Investment

Today KEI asked the Department of Commerce National Institute of Standards (NIST) to publish a notice in the Federal Register inviting comments on their Special Publication 1234, Draft Green Paper on Return on Public Investment, with an extended deadline. The… Continue Reading

Italy’s Draft WHO resolution: Improving the transparency of markets for drugs, vaccines and other health-related technologies

On 1 February 2019, Dr. Giulia Grillo, Italy’s Minister of Health, sent a letter to Dr. Tedros Adhanom Ghebreyesus, the Director General of the World Health Organization (WHO), with an attached “first draft” of a resolution on “Improving the transparency… Continue Reading

WTO TRIPS Council: Submission of the European Union, the United States and 9 other WTO members on Public-Private Collaborations in Innovation

On 8 February 2019, the World Trade Organization (WTO) published a submission (IP/C/W/652) by Australia; Canada; Chile; The European Union; Hong Kong, China; Japan; the Republic of Korea; Singapore; Switzerland; Chinese Taipei; and the United States to the TRIPS Council… Continue Reading

WTO TRIPS Council: South Africa considers strict patentability criteria to address abuses in the pharmaceutical industry

On 1 February 2019, the World Trade Organization (WTO) published a submission (IP/C/W/651) by South Africa to the TRIPS Council on Intellectual Property and the Public Interest: Promoting Public Health Through Competition Law and Policy. The South African paper endeavors… Continue Reading

WHO Cancer Report – Key findings

On 18 December 2018, the World Health Organization (WHO) published a “Technical report on Pricing of cancer medicines and its impacts” (hereinafter referred to as the “WHO Cancer Report”). The mandate for the WHO Cancer Report emanates from operative paragraph… Continue Reading

KEI Comments Regarding the NIST Special Publication 1234 Draft Green Paper on Return on Public Investment

KEI filed comments on the NIST Draft Green paper on the return from investment on federally funded R&D (See: https://www.keionline.org/29518). We expect the comment period to be extended, but filed this on January 9, 2018, as an initial submission. KEI-comments-NIST-SP-1234-ROI-9Jan2018… Continue Reading

2019: Joint Comments on NIH Prospective License to Medigen on RSV and Parainfluenza Vaccines

On January 7, 2019, KEI and MSF (Doctors Without Borders/Médecins Sans Frontières USA) submitted comments to the Federal Register notice (83 FR 65696) on the “Prospective Grant of Exclusive Patent License: Production of Live Respiratory Syncytial Virus and Parainfluenza Virus… Continue Reading

2019: Joint Comments on NIH Prospective License to Sixfold Biosciences on Nanoparticles Technology

On Monday January 7, 2019, KEI submitted joint comments on behalf of Health GAP, Social Security Works, the Union for Affordable Cancer Treatment, and Professor Brook Baker of Northeastern University to the Federal Register notice (83 FR 65694) for the”Prospective… Continue Reading